Enhancement of maternal lactation performance during prolonged lactation in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression

Darryl L Hadsell1,2, Albert F Parlow3, Daniel Torres1, Jessy George1 and Walter Olea1

1Department of Pediatrics, Baylor College of Medicine, USDA/ARS Children's Nutrition Research Center, Houston, Texas 77030, USA
2Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
3National Hormone Peptide Program, Harbor-UCLA Medical Center, Torrance, California 90509, USA

(Correspondence should be addressed to D L Hadsell; Email: dhadsell@bcm.tmc.edu)

Abstract

GH, prolactin (PRL), and IGF-I stimulate lactation-related metabolic processes in mammary epithelial cells. However, the ability of these factors to stimulate milk production in animals varies depending on species and experimental variables. Previous work in our laboratory demonstrated that transgenic overexpression of des(1–3)IGF-I within the mammary glands of lactating mouse dams increased lactation capacity during prolonged lactation. This work also suggested that some of the effects of the overexpressed IGF-I may have been mediated through elevated concentrations of IGF-I or PRL in the systemic circulation. In the present study, murine GH and PRL, and a human IGF-I analog, long-R3-IGF-I (LR3), were administered as s.c. injections to compare their ability to enhance milk production, and alter mammary gland signaling and gene expression. Lactation capacity, as measured by litter gain, was increased (P<0.05) by GH, but not by PRL. LR3 increased (P<0.05) mammary phospho-Akt and suppressors of cytokines signaling 3 (SOCS3) gene expression, and had a modest ability to increase (P<0.05) lactation capacity. GH both increased (P<0.05) mammary SOCS1 expression and decreased (P<0.05) mammary expression of tryptophan hydroxylase 1, the rate-limiting enzyme in the synthesis of serotonin and a potential feedback inhibitor of lactation. These results suggest that while both GH and IGF-I stimulate milk production in the lactating mouse, the effect of GH may be additionally mediated through IGF-I-independent effects associated with repression of mammary serotonin synthesis.

Journal of Endocrinology (2008) 198, 61–70

Introduction

Insulin-like growth factor I (IGF-I) is known to mediate the actions of growth hormone (GH) on peripheral tissues (Daughaday 2000). Prior studies on the mammary gland have suggested that some of the effects of GH on lactation might also be mediated through the actions of IGF-I (Dehoff et al. 1988, Prosser et al. 1990). In dairy cows, GH allows for milk production to maintain at higher levels for a longer period of time producing enhanced ‘lactation persistence’ (Bauman 1992, van Amburgh et al. 1997). This enhancement of lactation persistence has been suggested to be a valuable means of improving the well-being of dairy animals as well as enhancing profitability of dairy operations (van Amburgh et al. 1997). To take advantage of the power of mouse genetics, our laboratory has developed a litter cross-fostering approach that allows for studies on lactation persistence to be conducted using mice as a model for dairy animals (Hadsell et al. 2006, 2007). Following this approach, we demonstrated increased lactation persistence in a strain of transgenic mice (WAP-DES) that overexpress des(1–3)human IGF-I (hIGF-I) within the mammary gland (Hadsell et al. 2005). Increased lactation capacity was evident as improved weight gain in cross-fostered litters and was associated with enhanced mammary gland development and wet weight. This increased performance was also associated with higher maternal lean body mass and elevated circulating concentrations of both des(1–3)hIGF-I and prolactin (PRL). Studies with IGF-I null mice have also provided data to suggest that some of the effects of IGF-I may be mediated through the regulation of PRL secretion by the pituitary (Stefaneanu et al. 1999). These observations support the hypothesis that some of the effects of GH and IGF-I on milk production during prolonged lactation may be due to indirect systemic effects mediated through PRL-dependent or other endocrine systems.

Data from a number of experimental models have shown that activation of the JAK/STAT pathway is a direct consequence of PRL or GH stimulation in COS cells expressing the receptors for these hormones (Gouilleux et al. 1995). Studies in our own laboratory have demonstrated that...
i.v. injection of recombinant murine PRL into the tail vein of a lactating mouse profoundly increases mammary STAT5 phosphorylation within minutes (Hadsell et al. 2007). On the other hand, IGF-I signals through several pathways including the phosphoinositide 3 (PI3)-kinase/Akt and JAK/STAT pathways (Dudek et al. 1997, Gual et al. 1998). Our own studies using i.v. injections of the long-R3 (LR3) analog of IGF-I, a form that has enhanced potency due to an inability to interact with IGF-binding proteins, demonstrated increased phosphorylation of both Akt and STAT5 within the mammary gland within minutes of injection (Lee et al. 2003, Hadsell et al. 2007). Although these observations suggest that both ligands have the capacity to activate short-term signaling events within the mammary tissue of lactating mice, the effects of chronic treatment via s.c. injections have not been studied.

In the mammary gland, the ability of PRL to simulate milk synthesis may be limited by the induction of negative feedback inhibitors such as the suppressors of cytokines signaling (SOCS) genes (Sutherland et al. 2007). The most commonly studied members of this family include SOCS1, SOCS2, and SOCS3, and cytokine-inducible SH2 protein (CIS). In addition to potential effects on PRL signaling, the SOCS genes have also been found to play a feedback-inhibitory role in systems involving GH, IGF-I, and insulin (Ueki et al. 2004, Inaba et al. 2005, LeRoith & Nisley 2005). There may also be other local feedback inhibition mechanisms within the gland that regulate milk production (Knight et al. 1998). Tryptophan hydroxylase 1 (TPH1) is one of the two isozymes, which catalyzes the rate-limiting step in serotonin biosynthesis (Fitzpatrick 1999). In the mammary gland, TPH1 was identified in a suppressive subtractive hybridization screen for genes dependent on PRL (Matsuda et al. 2004). Studies on the role of TPH1 in the mammary gland have led to the suggestion that serotonin produced through the actions of this enzyme in mammary secretory cells acts as a feedback inhibitor of lactation (Matsuda et al. 2004).

The primary goal of these studies was to compare the impact of LR3-IGF-I, recombinant murine PRL, or recombinant murine GH on milk production, and mammary gland development in the mouse during prolonged lactation. A second goal of the study was to determine whether the effects of these hormonal treatments on lactation capacity could be related to changes in mammary cell signaling, and mammary expression of the SOCS, CIS, and TPH1 genes.

Materials and Methods

Experimental animals

All animals were studied in accordance with procedures outlined in the NIH Guide to Care and Use of Experimental Animals. These experiments were approved by the Baylor College of Medicine Animal Care and Use Committee. Mouse dams from the CD-1 strain (Charles River Laboratories, Wilmington, MA, USA) were the experimental unit in all studies. All dams were analyzed in their first lactation and none were concurrently pregnant during the course of these studies. Each dam received a cross-fostered litter of ten 1-day-old pups beginning on day 1 post partum to control for litter size. In addition, litter weights were equalized across all dams. Lactation was prolonged out to 37 days by cross-fostering 7-day-old pups onto each dam every 7 days as previously described (Hadsell et al. 2005, 2006). The relative maternal capacity for milk production was estimated using the weight gain of these independent cross-fostered litters during each of four 7-day periods, days 7–14, 14–21, 21–28, and 28–35. Beginning on day 14 post partum, the dams were given s.c. injections (0-1 ml) of saline or saline containing recombinant LR3-IGF-I (JRH Biosciences, Sigma–Aldrich, www.sigmaaldrich.com/) and recombinant murine GH (National Hormone and Pituitary Program, Torrance, CA, USA) or recombinant murine PRL (National Hormone and Pituitary Program). The number of dams per treatment group was 15, 15, and 10 for saline, LR3, and GH respectively. Injections were administered three times per day at 0800, 1400, and 2000 h respectively. The dose injected was 1·4 and 2·2 mg/kg body weight for LR3 and GH respectively. The ability of PRL to increase lactation capacity was tested in two separate experiments at a dose of either 1 or 4 mg/kg body weight respectively. The number of dams per treatment group was five in the first experiment and ten in the second one. Body composition of the dams was measured on day 36 by scanning each animal once with a PIXIImus (Lunar Corp., Madison, WI, USA) dual X-ray absorptiometer as previously described (Nagy & Clair 2000). Mammary glands were harvested on day 37 at 2–4 h following the last injection that was administered at 0800 h. Sampling was timed among the all treatment groups to balance the interval between the last injection and the tissue collection. At the time of harvesting, wet weights were recorded on each of the two no. 4 mammary glands, also known as inguinal glands, located on either side of the ventral midline just slightly anterior to the rear legs. The glands were then either flash-frozen in liquid nitrogen and stored at −80°C for further analysis or frozen in optimal cutting temperature (OCT)-embedding medium for cryosectioning. Plasma samples were prepared from trunk blood collected at the time of killing.

Mammary gland development

Epithelial content of the mammary tissue and alveolar luminal area was determined by segmentation analysis of images captured from hematoxylin- and eosin-stained mammary tissue sections. For each specimen, ten digital images were captured from randomly chosen fields using a Spot RT CCD (Diagnostic Instruments, Sterling Heights, MI, USA). Images were then coded to prevent investigator bias in the processing and analysis. For the measurement of percent epithelial area, the images manually processed using pixel selection tools within Adobe Photoshop 5.0 (Adobe Systems). This processing consisted of selection of the stromal elements

Journal of Endocrinology (2008) 198, 61–70

www.endocrinology-journals.org
within each image followed by pseudo-coloring to produce a binary image consisting of stromal and epithelial compartments. For the measurement of alveolar area, the major and minor axes of an ellipse, which would approximate each alveolus, were manually drawn onto the alveoli within each image. Images containing these drawn axes were then converted to binary images. The resulting binary images were then analyzed using Image Pro 5.1 (Media Cybernetics, Silver Spring, MD, USA). For epithelial area, the pixel area occupied by epithelium in each image was directly measured and expressed as a percentage of the entire image. For luminal area, the major and minor axes for each ellipse were measured in pixels and then converted to micrometers. Luminal areas were then calculated using the formula for an ellipse, \( \pi (L/2 + W/2) \), where \( L \) is the major axis and \( W \) is the minor axis.

**Hormone measurements**

The plasma concentrations of both human and murine IGF-I were measured using ELISA-based assays. The hIGF-I assay was a non-extraction IGF-I ELISA (Diagnostic Systems Laboratories, Inc., Webster, TX, USA) with a sensitivity of 20 ng/ml and an intra-assay coefficient of variation of 5–9%. Murine IGF-I was measured using a rat/mouse-specific immunoenzymometric assay (Immunodiagnostic Systems, Inc., Fountain Hills, AZ, USA) with a sensitivity of 82 ng/ml and an intra-assay coefficient of variation of 5–7%. Plasma progesterone was measured using a commercially available RIA (Diagnostic Systems Laboratory). This assay had a sensitivity of 0.1 ng/ml using 25 μl plasma, and an intra-assay coefficient of variations of 5-6 and 3-3% respectively. For the analysis of plasma PRL and GH, the samples were shipped on dry ice to the National Hormone and Pituitary Program. The intra-assay coefficients of variation for these assays were 4.2 and 4.4% respectively. The RIA immunoreagents are distributed to researchers on request by the National Institute of Diabetes and Digestive and Kidney Diseases, National Hormone and Pituitary Program.

**Western blotting**

Total tissue protein extracts of mammary tissue were prepared from 50 mg tissue and western blotting was conducted as previously described (Hadsell et al. 2003). Briefly, blots were prepared using PROTRAN nitrocellulose (Schleicher & Schuell, Keene, NH, USA). Detection was based on enhanced chemiluminescence using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA), and BioMax MR film (Kodak). Phospho-Akt was measured using an antibody (1:1000 dilution) to phospho-Ser\(^{73}\) that reacts with all three Akt isoforms (Cell Signaling Technology, Beverly, MA, USA). Phospho-ERK1/2 was also measured by western blotting as previously described (Hadsell et al. 2001). Equality of protein loading was ensured by running all samples on parallel gels that were subsequently stained with Coomassie blue. Densitometry data were acquired from the fluorograms using Scion Image (Scion Corporation, Frederick, MA, USA). All densitometry data were corrected for variations in loading using densitometry data obtained from the Coomassie-stained gels.

**Gene expression analysis**

RNA was isolated from a piece of the no. 4 mammary gland using Trizol reagent (Invitrogen). The isolated RNA was quantitated using a NanoDrop spectrophotometer. Taqman Gene Expression Assays (Applied Biosystems, Inc., Foster City, CA, USA) were used to quantitate mRNA for SOCS1 (Mm00782550_s1), SOCS2 (Mm00850544_g1), SOCS3 (Mm00545913_s1), CIS (Mm00515488_m1), and TPH1 (Mm00493794_ml) by quantitative RT-PCR. The 18S rRNA (X03205.1) was quantitated in each sample as a loading control. All of the Taqman assays used in this study were validated by the manufacturer over a six log dilution range and have efficiencies of 100 ± 10%. The intra-assay coefficients for variation for the assays ranged from 7.1 to 10.7%. Reverse transcription was performed on 10 ng RNA using Taqman reverse transcription reagents. The reaction mixture was 10 ng RNA, 1× RT buffer, 5-5 mM magnesium chloride, 2.5 μM random hexamers, 4 units RNase inhibitor, and 31-25 units MultiScribe reverse transcriptase. Reactions were incubated in an MJ Research PTC-200 Peltier Thermal Cycler (Bio-Rad Laboratories). The conditions were 10 min at 25 °C, 1 h at 37 °C, and 5 min at 95 °C. The reactions were placed in a well of a MicroAmp optical 96-well reaction plate (Applied Biosystems) and mixed with a 40 μl PCR mix containing 1× Taqman Universal PCR MasterMix and 1× Taqman Gene Expression Assay. Q-PCR was performed in a 7900 Fast Real-Time PCR System (Applied Biosystems). The reactions were incubated at 50 °C for 2 min, then at 95 °C for 10 min. The reactions were then cycled 40 times at 95 °C for 15 s and at 60 °C for 1 min. \( \Delta C_t \) was calculated from the \( C_t \) values of the gene of interest and the sample's 18S rRNA content. Fold changes in the mRNA levels were calculated in relation to the saline controls as previously described (Livak & Schmittgen 2001).

**Data analysis**

Litter weight gain data were analyzed in three ways. First, the repeated measures procedure of SPSS (version 12.01 for Windows; SPSS Inc, Chicago, IL, USA) was used to compare weekly weight gain of each cross-fostered litter. The model
for this analysis used injection (LR3 versus GH versus saline) as the fixed variable, day post partum as a repeated measure within each dam, and litter gain during the pretreatment week as a covariate. Second, the same repeated measures procedure was used to compare the second derivative of weekly litter gain for each of the 3 weeks that the injections were administered. Finally, total weight gain of the cross-fostered litters for the entire 3-week period was compared using a one-way ANOVA. The model for this analysis used injection as a fixed variable and litter gain during the pretreatment week as a covariate. Maternal body weight data were analyzed using a repeated measures analysis. The model for this analysis used injection as a fixed variable, day post partum as a repeated measure within each dam, and maternal bodyweight during the pretreatment week as a covariate. Data for body composition, mammary weight, epithelial area, plasma IGF-I, plasma progesterone, western blotting, and real-time qRT-PCR were analyzed using a one-way ANOVA. Specific treatment group comparisons were then done using a one-way ANOVA by predefined contrasts between the saline-injected group and each of the other three treatment groups. All the data are presented as means ± s.e.m. Differences were considered statistically significant at \( P \leq 0.05 \).

**Results**

Our previous work on prolonged lactation in the mouse demonstrated that transgenic mice that overexpressed IGF-I within the mammary gland exhibited increased milk production during prolonged lactation (Hadsell et al. 2005). We also found that this enhanced lactation capacity was associated with a significant increase in the circulating concentrations of IGF-I and PRL, increased maternal body mass, and increased maternal lean tissue mass. To follow up on these results, we chose to compare the impact of exogenous LR3, GH, or PRL on milk production in lactating mouse dams during prolonged lactation. Based on the results of previous studies with rats and mice, we administered the hormones as s.c. injections three times per day (Noel & Woodside 1993, Capuco et al. 1999). To confirm that our injection protocols provided an adequate dose and injection frequency to elevate circulating levels of these hormones, plasma samples were collected at either 4 or 8 h after the last injection depending on the experiment.

The first experiment to determine the ability of exogenous PRL to enhance lactation persistence used a dose that was shown to be biologically effective in previously published studies with both rats and mice (Noel & Woodside 1993, Capuco et al. 1999). In this initial experiment, an s.c. daily dose of 1 mg/kg of murine PRL failed to increase lactation performance (Fig. 1A) and had no impact on maternal body weight (Fig. 1C). This dose of PRL also failed to increase maternal plasma PRL (157 ± 63 and 94 ± 38 ng/ml for saline- and PRL-injected dams respectively). On the basis of this study, a second PRL experiment was conducted using a dose that was 4 mg/kg per day. In this second study, circulating

**Figure 1** Exogenous administration of murine PRL has no impact on lactation capacity during prolonged lactation. The effect of exogenous recombinant murine PRL on (A and B) lactation capacity and (C and D) maternal body weight was measured in two separate experiments at a dose of either (A and C) 1 or (B and D) 4 mg/kg body weight/day. (A and B) Relative lactation capacity was estimated by comparing weekly weight gain of cross-fostered, weight-normalized, litters containing ten 7-day-old pups each among PRL- (●) and saline-injected (○) dams. (C and D) Maternal body was also compared between the two groups within each experiment. Each symbol represents the mean ± s.e.m. for five dams each in (A and C) and ten dams each in (B and D). The asterisk indicates a statistically significant (\( P \leq 0.05 \)) increase in maternal body weight.
maternal PRL concentrations were elevated \( (P<0.05) \) in the PRL-injected group (32 ± 9 and 1400 ± 588 ng/ml in saline- and PRL-injected dams respectively), but lactation capacity was still similar to that of saline-injected dams (Fig. 1B). Maternal body weight, however, was higher \( (P<0.05) \) in dams receiving PRL at 4 mg/kg per day than that of dams receiving saline (Fig. 1D). Interestingly, the high dose of PRL injected in the second experiment also decreased \( (P<0.05) \) maternal circulating concentrations of both progesterone and IGF-I. For progesterone, the concentrations were reduced in PRL-injected dams to 10% of that found in the saline-injected controls (2 ± 1 and 21 ± 4 ng/ml respectively). Maternal circulating IGF-I concentrations in PRL-injected dams were reduced to 77% of that found in the saline-injected group (399 ± 45 and 515 ± 27 ng/ml respectively).

The ability of LR3 to increase maternal lactation capacity in mice was tested using a dose similar to one that was previously shown to be biologically effective in mice (Stabnov et al. 2002). At a dose of 1.4 mg/kg per day, the concentration of hIGF-I in LR3-injected dams was 130 ± 26 ng/ml. There was no hIGF-I reactivity detectable in saline-injected dams. At this dose, LR3 had a modest capacity to increase weekly litter weight gain (Fig. 2A) and total litter gain \( (P<0.05) \) over the 3-week treatment period (Fig. 2A inset). In addition, LR3 increased \( (P<0.05) \) maternal body weight (Fig. 2B). The maternal circulating concentrations of endogenous murine IGF-I were similar between saline- and LR3-injected dams (515 ± 27 and 476 ± 20 ng/ml respectively). In addition, the maternal circulating concentrations of progesterone were similar between saline- and LR3-injected dams (21 ± 4 and 20 ± 2 ng/ml respectively).

The ability of GH to increase maternal lactation capacity in mice was tested using a dose similar to one that was previously shown to be biologically effective in rats (Groesbeck et al. 1987). When administered at a dose of 2 mg/kg per day, GH increased \( (P<0.01) \) both lactation capacity (Fig. 2A) and maternal body weight (Fig. 2B). The effect of lactation capacity was observed both in terms of weekly litter gain (Fig. 2A) and total litter gain (Fig. 2A inset). The maternal circulating concentration of GH was significantly increased \( (P<0.05) \) by GH injections (5.5 ± 1.7 and 305 ± 184 ng/ml in saline- and GH-injected dams respectively). The concentrations of endogenous murine IGF-I in circulation were also increased \( (P<0.05) \) in GH-injected dams (515 ± 27 and 729 ± 41 ng/ml for saline- and GH-injected respectively). In addition, the weight of the no. 4 mammary glands was higher \( (P<0.05) \) in GH- than saline-injected dams, and morphometric analysis of hematoxylin-eosin-stained mammary tissue sections demonstrated that alveolar lumenal area was also increased \( (P<0.05) \) in GH-injected dams (Fig. 2C).

Neither LR3 nor PRL had a significant impact on mammary gland wet weight or morphology.

Because GH, LR3, and PRL all had the capacity to alter maternal body weight, DEXA analysis was used to determine whether maternal body composition was changed by these treatments as well. Maternal lean body mass (Lean) and total bone area (Area) were higher \( (P<0.0001) \) in LR3- and GH-treated dams than those in saline-injected dams (Table 1). Bone mineral content was higher \( (P<0.05) \) in LR3-treated dams than that in PRL-injected dams while percent body fat was lower \( (P<0.05) \) in GH-treated dams than that in saline-injected dams.
Having observed a differential ability of GH, LR3, and PRL to enhance milk production during prolonged lactation, we next wanted to determine whether these differences could be accounted for by potential differences in the ability of these factors to activate mammary signaling pathways or alter mammary gland gene expression. To measure the activation of signaling pathways that might be expected to be induced by IGF-I, western blotting was conducted for phospho-Akt and dual-phosphorylated ERK1/2 on mammary tissue samples that were collected at 4 h following the last s.c. injection of the 3-week treatment protocol (Fig. 3). This analysis demonstrated that phosphorylation of Ser 473 on mammary Akt was higher (*P*! 0.05) in LR3-injected dams than that in saline-injected dams (Fig. 3A). Total Akt was not altered by any of the treatments (data not shown). Neither GH nor PRL had any effect on mammary Akt phosphorylation. Neither phospho-ERK1/2 nor total ERK1/2 was changed by any of the treatments (Fig. 3B).

To test for potential activation of pathways expected to be induced by PRL and GH, we used western blotting to measure phosphorylation of STAT5 and STAT3 (Fig. 4A and B). Phosphorylation of mammary STAT5 on Tyr 694 was not affected by any of the treatments (Fig. 4A). Mammary abundance of total STAT5 was not affected by any of the treatments (data not shown). Phosphorylation of mammary STAT3 on Tyr 705 was increased (*P*! 0.05) in PRL-injected dams relative to that observed in saline-injected dams (Fig. 4B).

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>BMD</th>
<th>BMC</th>
<th>Area</th>
<th>Lean</th>
<th>Fat</th>
<th>Fat (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sal</td>
<td>0.05±0.001</td>
<td>0.48±0.011*</td>
<td>10.13±0.22</td>
<td>29.14±0.48*</td>
<td>2.71±0.17</td>
<td>8.57±0.43*</td>
</tr>
<tr>
<td>Prl</td>
<td>0.05±0.001</td>
<td>0.47±0.011*</td>
<td>10.06±0.18</td>
<td>29.83±0.55*</td>
<td>2.98±0.20</td>
<td>8.96±0.50*</td>
</tr>
<tr>
<td>LR3</td>
<td>0.05±0.001</td>
<td>0.52±0.011*</td>
<td>11.06±0.18</td>
<td>34.58±0.55</td>
<td>2.77±0.20</td>
<td>7.49±0.50*</td>
</tr>
<tr>
<td>GH</td>
<td>0.05±0.001</td>
<td>0.50±0.02*</td>
<td>10.86±0.22</td>
<td>34.22±0.68</td>
<td>2.30±0.24</td>
<td>6.59±0.61*</td>
</tr>
<tr>
<td>P</td>
<td>0.8</td>
<td>0.026</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>0.2</td>
<td>0.013</td>
</tr>
</tbody>
</table>

*Means with different superscripts differ (*P*! 0.05).

aBone mineral density.
bTotal bone mineral content.
cTotal bone area.
dLean tissue mass.
eFat tissue mass.
fPercent body fat.

Having observed a differential ability of GH, LR3, and PRL to enhance milk production during prolonged lactation, we next wanted to determine whether these differences could be accounted for by potential differences in the ability of these factors to activate mammary signaling pathways or alter mammary gland gene expression. To measure the activation of signaling pathways that might be expected to be induced by IGF-I, western blotting was conducted for phospho-Akt and dual-phosphorylated ERK1/2 on mammary tissue samples that were collected at 4 h following the last s.c. injection of the 3-week treatment protocol (Fig. 3). This analysis demonstrated that phosphorylation of Ser 473 on mammary Akt was higher (*P*! 0.05) in LR3-injected dams than that in saline-injected dams (Fig. 3A). Total Akt was not altered by any of the treatments (data not shown). Neither GH nor PRL had any effect on mammary Akt phosphorylation. Neither phospho-ERK1/2 nor total ERK1/2 was changed by any of the treatments (Fig. 3B).

To test for potential activation of pathways expected to be induced by PRL and GH, we used western blotting to measure phosphorylation of STAT5 and STAT3 (Fig. 4A and B). Phosphorylation of mammary STAT5 on Tyr 694 was not affected by any of the treatments (Fig. 4A). Mammary abundance of total STAT5 was not affected by any of the treatments (data not shown). Phosphorylation of mammary STAT3 on Tyr 705 was increased (*P*! 0.05) in PRL-injected dams relative to that observed in saline-injected dams (Fig. 4B).

**Figure 3** Exogenous administration of LR3, but not GH or PRL, increases phosphorylation of mammary Akt. Western blotting for phospho-Akt, dual phosphorylated ERK1/2, total Akt, and total ERK1/2 was conducted on extracts prepared from mammary tissue samples collected on day 37 post partum from lactating dams receiving s.c. injections of either saline, LR3, GH, or PRL respectively. Tissue samples were collected at 2–4 h following the last injection. Densitometry was conducted to quantitatively compare the ratios of phosphorylated with total (A) Akt and (B) ERK1/2. Each bar represents the mean ± S.E.M. for 20, 15, 10, and 10 dams in the saline, LR3, PRL, and GH treatment groups respectively. The asterisk indicates a statistically significant (*P*! 0.05) increase relative to that observed for the saline-injected group.

**Figure 4** Exogenous administration of prolactin, but not GH or LR3, increases STAT3 phosphorylation within the mammary glands of mouse dams during prolonged lactation. Western blotting for phospho-STAT5, phospho-STAT3, total STAT5, and total STAT3 was conducted on extracts prepared from mammary tissue samples collected on day 37 post partum from lactating dams receiving s.c. injections of either saline, LR3, GH, or PRL respectively. Tissue samples were collected at 2–4 h following the last injection. Densitometry was conducted to quantitatively compare the levels of the ratios of phosphorylated with total (A) STAT5 and (B) STAT3. Each bar represents the mean ± S.E.M. for 20, 15, 10, and 10 dams in the saline, LR3, PRL, and GH treatment groups respectively. The asterisk indicates a statistically significant (*P*! 0.05) increase relative to that observed for the saline-injected group.
(Fig. 4B). Abundance of total STAT3 in the mammary gland was not affected by any of the treatments (data not shown).

Because the expression of the SOCS genes can be induced in mammary tissue and other organs by cytokines and growth factors, we measured the mRNA levels of SOCS1, SOCS2, SOCS3, and CIS. We also measured the mRNA levels of TPH1, a gene that regulates the synthesis of serotonin, another potential feedback inhibitor of lactation. Real-time RT-PCR was used on total mammary RNA with probe and primer sets for the murine 18S rRNA, SOCS1, SOCS2, SOCS3, CIS, and TPH1 (Fig. 5). Normalized threshold values (CT) were obtained by using primer probe sets for the murine 18S rRNA. Comparison of the CT values for the 18S assay among the treatments demonstrated that this mRNA was not altered by the different hormonal treatments. Fold changes in the different genes were then calculated relative to the normalized CT for saline-injected dams (Fig. 5). The expression of SOCS1 was twofold higher ($P<0.05$) in mammary tissue of GH-injected dams than that of saline-injected dams (Fig. 5A). The mRNA for SOCS3 was twofold higher ($P<0.05$) in mammary tissue of LR3-injected dams than that of saline-injected dams (Fig. 5C). In addition, the mRNA for TPH1 in mammary tissue of GH-treated dams was reduced ($P<0.05$) to about 40% of that observed in saline-treated dams (Fig. 5D). None of the genes analyzed were perceptibly impacted by PRL in this study.

**Discussion**

These studies demonstrate for the first time that recombinant murine GH and LR3-IGF-I can increase maternal lactation capacity during prolonged lactation in the mouse. These data, combined with the observation that mammary gland wet weight and alveolar lumen area were both increased in GH-injected dams, support the conclusion that milk production was increased in response to GH and more modestly so in response to LR3. At this point, it is important to mention two caveats. The first is that litter weight gain could have been affected by changes in milk macronutrient content. In this regard, although we did not collect milk composition data, several previously published observations, including our own, suggest that the effects of GH and LR3 were due to changes in milk production, not in milk composition (Austin et al. 1991, Flint & Gardner 1994, Hadsell et al. 2005). The second caveat is that mammary gland morphology and wet weight could have been influenced by the timing of tissue sampling relative to the last nursing event between each dam and its pups. While this is meritorious, published data on maternal behavior in rodents, including our own analysis of maternal behavior in mice during prolonged lactation, suggest that because sample collection took place during the day (1000–1200 h), the time period of separation between the dam and its litter would have been no longer than 20 min and was probably much shorter (Sodersten & Eneroth 1984, Hoshino et al. 2006, Hadsell et al. 2007). These observations strongly support the conclusion that the effects of GH and LR3 were mediated through changes in milk production. Combined with the cell signaling and gene expression data, the results also suggest a novel mechanism for GH action in the mammary gland that involves direct effects through the TPH1 gene and indirect effects through the IGF-I-mediated Akt activation. In addition, our results suggest that previously observed increases in lactation capacity in transgenic mice that overexpress des(1–3)hIGF-I were probably not mediated by increased circulating PRL (Hadsell et al. 2005). An important question that remains, however, is why these hormones are effective under some experimental conditions and in some species, but not others?

Numerous studies have examined the impact of PRL, GH, and IGF-I on milk production in lactating cows, goats, and rats respectively (Tucker 1974, Flint et al. 1984, 1994, Plaut et al. 1987, Davis et al. 1989, Prosser et al. 1990, Flint & Gardner 1994). Eneroth et al. 1984, 1994, Plaut et al. 1987). These studies demonstrate for the first time that recombinant murine GH and LR3-IGF-I can increase maternal lactation capacity during prolonged lactation in the mouse. These data, combined with the observation that mammary gland wet weight and alveolar lumen area were both increased in GH-injected dams, support the conclusion that milk production was increased in response to GH and more modestly so in response to LR3. At this point, it is important to mention two caveats. The first is that litter weight gain could have been affected by changes in milk macronutrient content. In this regard, although we did not collect milk composition data, several previously published observations, including our own, suggest that the effects of GH and LR3 were due to changes in milk production, not in milk composition (Austin et al. 1991, Flint & Gardner 1994, Hadsell et al. 2005). The second caveat is that mammary gland morphology and wet weight could have been influenced by the timing of tissue sampling relative to the last nursing event between each dam and its pups. While this is meritorious, published data on maternal behavior in rodents, including our own analysis of maternal behavior in mice during prolonged lactation, suggest that because sample collection took place during the day (1000–1200 h), the time period of separation between the dam and its litter would have been no longer than 20 min and was probably much shorter (Sodersten & Eneroth 1984, Hoshino et al. 2006, Hadsell et al. 2007). These observations strongly support the conclusion that the effects of GH and LR3 were mediated through changes in milk production. Combined with the cell signaling and gene expression data, the results also suggest a novel mechanism for GH action in the mammary gland that involves direct effects through the TPH1 gene and indirect effects through the IGF-I-mediated Akt activation. In addition, our results suggest that previously observed increases in lactation capacity in transgenic mice that overexpress des(1–3)hIGF-I were probably not mediated by increased circulating PRL (Hadsell et al. 2005). An important question that remains, however, is why these hormones are effective under some experimental conditions and in some species, but not others?
Only a few studies have examined the impact of these hormones on lactation in the mouse (Nandi 1958a, b, Capuco et al. 1999, Hadsell et al. 2005). The data presented in this paper are the first to compare the effects of these three hormones on milk production, mammary cell signaling, and mammary gene expression during prolonged lactation in the mouse.

All three hormones in this study had effects on maternal physiology, mammary cell signaling, or mammary gene expression. The PRL-injected dams exhibited increased body weight and altered circulating concentrations of both progesterone and IGF-I. The increased maternal body weight was probably a result of increased food intake since previous studies have demonstrated that PRL is orexigenic in rats (Byatt et al. 1993, Noel & Woodside 1993, Woodside 2007). Surprisingly, neither the expression of SOCS3 nor the phosphorylation of STAT5 was increased in the mammary glands of PRL-injected dams. Our own previous work on PRL signaling has shown that the recombinant murine PRL used in the present study is capable of inducing mammary STAT5 phosphorylation when administered intravenously to lactating mice (Hadsell et al. 2007). In addition, others have demonstrated that exogenous GH and PRL increased the expression of SOCS3 in the mammary tissue of virgin mice (Le Provost et al. 2005). In lactating rats, however, SOCS gene expression was induced by exogenous PRL only after 48 h of separation from their litters, suggesting that milk removal impacts the regulation of SOCS gene expression by PRL or other cytokines (Tam et al. 2001). In addition, differences in the route of administration, the duration of treatment, and the timing of sample collection may have impacted our ability to detect changes in STAT5 phosphorylation and induction of SOCS gene expression. Regardless, an effect of PRL on milk production might still have been detected if it were present.

The effects of PRL on milk production in normal lactating rats as well as in dairy cows have been largely negative with the exception of one study on prolonged lactation (Flint et al. 1984). Both PRL and GH have been demonstrated to support lactogenesis in hypophysectomized mice (Nandi 1958a, b) and both factors also stimulate milk production in lactating rats that have been treated with anti-GH antisera and bromocryptine (Flint & Gardner 1994). In addition, GH or PRL can increase lactation capacity in conjunction with thyroxine in hypothyroid lactating mice (Capuco et al. 1999). In dairy cows and goats, GH, but not PRL, has been shown to increase milk production (Plaut et al. 1987, Jacquemet & Prigge 1990, van Amburgh et al. 1997). In addition, short-term infusions of IGF-I have been found to increase milk synthesis in goats (Prosser et al. 1990). Our mouse data are consistent with the conclusion that milk production in normal lactating mice during prolonged lactation, as in cows and rats, is largely unresponsive to exogenous PRL. Our data are also consistent with the possibility that milk production may be more responsive to GH in mice than that in rats despite the fact that in both species PRL and GH elicit similar changes in maternal physiology that may not have been directly linked to milk production (Thatcher & Tucker 1970).

The impact of exogenous GH and LR3 on maternal physiology in this study was evident in a number of the endpoints examined. Both GH and LR3 increased maternal body weight. However, unlike PRL, these increases probably occurred through a different mechanism since they were associated with alterations in body composition. The body weight and composition effects in LR3-injected dams were similar to those previously observed during prolonged lactation in the WAP-DES mice (Hadsell et al. 2005). The results are also consistent with the reported ability of IGF-I to improve nitrogen retention in female rats (Tomas et al. 1993). Along with the effects on body composition, however, the fact that milk production was increased in three independent mouse studies suggests that IGF-I, like GH, may be more effective at stimulating milk production in mice than in rats (Flint et al. 1992, 1994, Su & Cheng 2004, Hadsell et al. 2005).

An important point to remember is that both LR3 and des(1–3)IGF-I are known to be more potent than wild-type, endogenous, IGF-I since they do not interact with IGF-binding proteins (Clemmons et al. 1992, Oh et al. 1993). From the standpoint of interactions with the type-I IGF receptor, des(1–3)IGF-I and wild-type IGF-I are equivalent, while LR3 has somewhat reduced affinity (Ballard et al. 1986, 1987, Bagley et al. 1989). The impact of this reduced affinity appears minimal from a biological standpoint since LR3 maintains greater potency than wild-type IGF-I in both in vitro and in vivo assays (Ballard et al. 1986, Tomas et al. 1993). Therefore, although endogenous IGF-I was elevated in the GH-injected dams, this elevation would be expected to have less of a biological effect than that found in the WAP-DES transgenic dams or the LR3-injected dams. Clearly, the LR3 impacted the gland since both Akt phosphorylation and SOCS3 gene expression were elevated. However, the milk production response to LR3 might have been greater if circulating concentrations were as high as those originally observed with the WAP-DES mice (Hadsell et al. 2005). In addition, the comparison of mammary cell signaling and gene expression between the LR3- and the GH-injected dams suggests the possibility that the impact of GH on milk production may be mediated through additional factors that are independent of IGF-I action. This point was evident from the fact that both SOCS1 and TPH1 gene expression were altered in mammary tissue of GH-injected mice, but not affected in LR3-injected dams. In addition, while SOCS3 might have also been expected to increase in mammary tissue of both the LR3- and GH-injected dams, it was only altered in response to LR3 (Adams et al. 1998, Yadav et al. 2005).

Among the most interesting aspects of the GH effects were the impact on mammary expression of the gene for TPH1. In the mammary gland, TPH1 controls the synthesis of serotonin, a factor that regulates the ability of PRL to support mammary gland development and milk synthesis (Matsuda et al. 2004). Targeted mutation of the TPH1 gene in mice inhibits mammary involution (Matsuda et al. 2004). The expression of TPH1 is inducible both by PRL and teat sealing, a treatment that inhibits activation of STAT5 and causes mammary gland
involution (Matsuda et al. 2004). The expression of TPH1 is also increased in the mammary tissue of lactating mice that are subjected to an interval nursing protocol that maintains lactation, but decreases the frequency of milk removal (Hadsell et al. unpublished data 2007). These observations, coupled with the fact that mammary expression of TPH1 was decreased in the GH-injected dams, suggest that some of the potential lactation-enhancing effects of GH may be mediated through decreased synthesis of mammary serotonin.

In summary, administration of exogenous GH, LR3–IGF-I, and PRL has significant effects on maternal physiology, mammary gland signaling, and mammary gene expression, yet only recombinant murine GH and LR3 were capable of enhancing lactation capacity in the litter cross-fostered mouse during prolonged lactation. A potential mechanism for the ability of GH to increase lactation capacity may lie in its ability to repress the expression of TPH1 within the mammary gland. This potential mechanism, and its regulation by the frequency of milk removal, will be the subject of future studies in both mice and dairy cows.

Declaration of Interest

The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

Funding

This project was supported by funds from NIH DK52197 (D L H), the USDA cooperative agreement no. 58-6250-6001 (D L H), and CSREES no. 2007-35206-17831 (D L H).

Acknowledgements

The authors would like to thank Dr Sonali Jain for assistance with the animal experiments. They also thank Dr Robert J Collier for a critical review of the manuscript.

References


Flint DJ & Gardner M 1994 Evidence that growth hormone stimulates milk synthesis by direct action on the mammary gland and that prolactin exerts effects on milk secretion by maintenance of mammary deoxynucleobolic acid content and tight junction status. Endocrinology 135 1119–1124.

Flint DJ, Clegg RA & Knight CH 1984 Effects of prolactin, progesterone and ovarioectomy on metabolic activities and insulin receptors in the mammary gland and adipose tissue during extended lactation in the rat. Journal of Endocrinology 102 231–236.


www.endocrinology-journals.org


